tiprankstipranks
Protagonist Therapeutics Inc (PTGX)
NASDAQ:PTGX
US Market
Want to see PTGX full AI Analyst Report?

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

744 Followers
See the Price Targets and Ratings of:

PTGX Analyst Ratings

Strong Buy
10Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Protagonist
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PTGX Stock 12 Month Forecast

Average Price Target

$131.11
▼(-3.67% Downside)
Based on 10 Wall Street analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is $131.11 with a high forecast of $165.00 and a low forecast of $110.00. The average price target represents a -3.67% change from the last price of $136.11.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"$52","109":"$109","166":"$166","80.5":"$80.5","137.5":"$137.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$165.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":131.11111111111111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$131.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,80.5,109,137.5,166],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,136.64,138.82153846153844,141.00307692307692,143.18461538461537,145.36615384615385,147.5476923076923,149.72923076923075,151.91076923076923,154.09230769230768,156.27384615384614,158.45538461538462,160.63692307692307,162.81846153846155,{"y":165,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,136.64,136.21470085470085,135.7894017094017,135.36410256410255,134.93880341880342,134.51350427350425,134.08820512820512,133.66290598290598,133.23760683760685,132.81230769230768,132.38700854700855,131.9617094017094,131.53641025641025,{"y":131.11111111111111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,136.64,134.5907692307692,132.54153846153844,130.4923076923077,128.44307692307692,126.39384615384614,124.34461538461538,122.2953846153846,120.24615384615385,118.19692307692307,116.14769230769231,114.09846153846154,112.04923076923077,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.24,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.37,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.92,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.64,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$165.00Average Price Target$131.11Lowest Price Target$110.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$100$155
Buy
13.88%
Upside
Reiterated
07/20/26
Analyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating
Citizens JMP Analyst forecast on PTGX
Citizens JMP
Citizens JMP
$137$165
Buy
21.23%
Upside
Reiterated
07/17/26
Protagonist Therapeutics price target raised to $165 from $137 at CitizensProtagonist Therapeutics price target raised to $165 from $137 at Citizens
Jefferies Analyst forecast on PTGX
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$121
Buy
-11.10%
Downside
Reiterated
07/16/26
Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
Truist Financial Analyst forecast on PTGX
Truist Financial
Truist Financial
Buy
Reiterated
07/16/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (NASDAQ: TGTX), Protagonist Therapeutics (NASDAQ: PTGX) and PROCEPT BioRobotics (NASDAQ: PRCT)
Barclays Analyst forecast on PTGX
Barclays
Barclays
$119$151
Buy
10.94%
Upside
Reiterated
07/14/26
Analysts' Top Healthcare Picks: HCA Healthcare (HCA), Protagonist Therapeutics (PTGX)
Goldman Sachs Analyst forecast on PTGX
Goldman Sachs
Goldman Sachs
$97$110
Hold
-19.18%
Downside
Reiterated
06/10/26
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX), Gilead Sciences (NASDAQ: GILD) and Edwards Lifesciences (NYSE: EW)
J.P. Morgan Analyst forecast on PTGX
J.P. Morgan
J.P. Morgan
$106$113
Buy
-16.98%
Downside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (NASDAQ: ANL), Protagonist Therapeutics (NASDAQ: PTGX) and Nuvalent (NASDAQ: NUVL)
H.C. Wainwright Analyst forecast on PTGX
H.C. Wainwright
H.C. Wainwright
$117
Buy
-14.04%
Downside
Reiterated
05/11/26
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Protagonist Therapeutics (PTGX)
Citi
$125$130
Buy
-4.49%
Downside
Reiterated
05/10/26
Protagonist Therapeutics price target raised to $130 from $125 at CitiProtagonist Therapeutics price target raised to $130 from $125 at Citi
Wedbush Analyst forecast on PTGX
Wedbush
Wedbush
$112$118
Buy
-13.31%
Downside
Assigned
05/06/26
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (NASDAQ: TEM), Protagonist Therapeutics (NASDAQ: PTGX) and DENTSPLY SIRONA (NASDAQ: XRAY)
Clear Street Analyst forecast on PTGX
Clear Street
Clear Street
$104$116
Buy
-14.77%
Downside
Reiterated
04/06/26
Protagonist Therapeutics price target raised to $116 from $104 at Clear StreetProtagonist Therapeutics price target raised to $116 from $104 at Clear Street
Leerink Partners Analyst forecast on PTGX
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$107$110
Buy
-19.18%
Downside
Reiterated
03/19/26
Protagonist price target raised to $110 from $107 at LeerinkProtagonist price target raised to $110 from $107 at Leerink
BTIG
$82
Buy
-39.75%
Downside
Reiterated
11/03/25
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX) and Perspective Therapeutics (NYSE MKT: CATX)
BMO Capital Analyst forecast on PTGX
BMO Capital
BMO Capital
$72$112
Buy
-17.71%
Downside
Reiterated
10/13/25
Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital
Roth MKM Analyst forecast on PTGX
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$72
Buy
-47.10%
Downside
Initiated
09/17/25
Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$100$155
Buy
13.88%
Upside
Reiterated
07/20/26
Analyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating
Citizens JMP Analyst forecast on PTGX
Citizens JMP
Citizens JMP
$137$165
Buy
21.23%
Upside
Reiterated
07/17/26
Protagonist Therapeutics price target raised to $165 from $137 at CitizensProtagonist Therapeutics price target raised to $165 from $137 at Citizens
Jefferies Analyst forecast on PTGX
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$121
Buy
-11.10%
Downside
Reiterated
07/16/26
Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
Truist Financial Analyst forecast on PTGX
Truist Financial
Truist Financial
Buy
Reiterated
07/16/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (NASDAQ: TGTX), Protagonist Therapeutics (NASDAQ: PTGX) and PROCEPT BioRobotics (NASDAQ: PRCT)
Barclays Analyst forecast on PTGX
Barclays
Barclays
$119$151
Buy
10.94%
Upside
Reiterated
07/14/26
Analysts' Top Healthcare Picks: HCA Healthcare (HCA), Protagonist Therapeutics (PTGX)
Goldman Sachs Analyst forecast on PTGX
Goldman Sachs
Goldman Sachs
$97$110
Hold
-19.18%
Downside
Reiterated
06/10/26
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX), Gilead Sciences (NASDAQ: GILD) and Edwards Lifesciences (NYSE: EW)
J.P. Morgan Analyst forecast on PTGX
J.P. Morgan
J.P. Morgan
$106$113
Buy
-16.98%
Downside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (NASDAQ: ANL), Protagonist Therapeutics (NASDAQ: PTGX) and Nuvalent (NASDAQ: NUVL)
H.C. Wainwright Analyst forecast on PTGX
H.C. Wainwright
H.C. Wainwright
$117
Buy
-14.04%
Downside
Reiterated
05/11/26
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Protagonist Therapeutics (PTGX)
Citi
$125$130
Buy
-4.49%
Downside
Reiterated
05/10/26
Protagonist Therapeutics price target raised to $130 from $125 at CitiProtagonist Therapeutics price target raised to $130 from $125 at Citi
Wedbush Analyst forecast on PTGX
Wedbush
Wedbush
$112$118
Buy
-13.31%
Downside
Assigned
05/06/26
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (NASDAQ: TEM), Protagonist Therapeutics (NASDAQ: PTGX) and DENTSPLY SIRONA (NASDAQ: XRAY)
Clear Street Analyst forecast on PTGX
Clear Street
Clear Street
$104$116
Buy
-14.77%
Downside
Reiterated
04/06/26
Protagonist Therapeutics price target raised to $116 from $104 at Clear StreetProtagonist Therapeutics price target raised to $116 from $104 at Clear Street
Leerink Partners Analyst forecast on PTGX
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$107$110
Buy
-19.18%
Downside
Reiterated
03/19/26
Protagonist price target raised to $110 from $107 at LeerinkProtagonist price target raised to $110 from $107 at Leerink
BTIG
$82
Buy
-39.75%
Downside
Reiterated
11/03/25
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX) and Perspective Therapeutics (NYSE MKT: CATX)
BMO Capital Analyst forecast on PTGX
BMO Capital
BMO Capital
$72$112
Buy
-17.71%
Downside
Reiterated
10/13/25
Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital
Roth MKM Analyst forecast on PTGX
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$72
Buy
-47.10%
Downside
Initiated
09/17/25
Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Protagonist Therapeutics

3 Months
Brian ChengJ.P. Morgan
Success Rate
15/17 ratings generated profit
88%
Average Return
+18.28%
Copying Brian Cheng's trades and holding each position for 3 Months would result in 88.24% of your transactions generating a profit, with an average return of +18.28% per trade.
1 Year
Yun ZhongWedbush
Success Rate
17/17 ratings generated profit
100%
Average Return
+95.33%
Copying Yun Zhong's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +95.33% per trade.
2 Years
Douglas TsaoH.C. Wainwright
Success Rate
28/28 ratings generated profit
100%
Average Return
+193.26%
Copying Douglas Tsao's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +193.26% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTGX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
24
26
14
16
7
Hold
1
2
2
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
28
16
18
8
In the current month, PTGX has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. PTGX average Analyst price target in the past 3 months is 131.11.
Each month's total comprises the sum of three months' worth of ratings.

PTGX Financial Forecast

PTGX Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

PTGX Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

PTGX Stock Forecast FAQ

What is PTGX’s average 12-month price target, according to analysts?
Based on analyst ratings, Protagonist Therapeutics Inc’s 12-month average price target is 131.11.
    What is PTGX’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for PTGX, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is PTGX a Buy, Sell or Hold?
        Protagonist Therapeutics Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Protagonist Therapeutics Inc’s price target?
          The average price target for Protagonist Therapeutics Inc is 131.11. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $165.00 ,the lowest forecast is $110.00. The average price target represents -3.67% Decrease from the current price of $136.11.
            What do analysts say about Protagonist Therapeutics Inc?
            Protagonist Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
              How can I buy shares of PTGX?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.